Madrigal’s Rezdiffra tops $1B run-rate in MASH, but losses and rising GLP-1/FGF21 competition may cap upside into 2026. See ...
A heart surgeon bullying scandal, patients left to sleep on hospital floors and a push to cut Northern Ireland’s waiting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback